Kornimate/medical-research-clean huggingface dataset:
predicting adverse kidney events of cardiac surgery-associated acute kidney injury using novel biomarkers

Conditions: Acute Kidney Injury; Critical Illness; Kidney Failure

Summary: the aim of this study was to identify and validate novel biomarkers for predict acute kidney injury (aki) subphenotype, major adverse kidney events and other poor outcomes.

cardiac surgery-associated acute kidney injury (csa-aki) is a serious condition that is associated with increased mortality and morbidity. however, the current criteria for assessing the severity of aki may not adequately capture the heterogeneity of this condition. this can lead to difficulties in identifying treatment effects in specific patient subgroups, which may contribute to the growing number of negative interventional trials in aki. to address this issue, researchers have developed and validated two subphenotypes of aki: resolving and nonresolving. these subphenotypes are based on the trajectory of serum creatinine (scr) levels in the first 3 days after hospital presentation. by stratifying aki patients based on these subphenotypes, we can better assess their risk and predict outcomes. several novel biomarkers have been developed to aid in the early detection of aki, discrimination of its underlying causes, and prediction of outcomes. however, it remains unclear whether these biomarkers can accurately predict the development of a nonresolving aki subphenotype. in our present study, we aim to address this gap in knowledge by conducting a large cohort study. our goal is to identify and validate novel biomarkers that can effectively detect the resolving subphenotype of aki, as well as predict major adverse kidney events and other poor outcomes.

Eligibility criteria:
inclusion criteria: * patients undergoing cardiac surgery who experienced aki within 48 hours of cardiac surgery were screened. exclusion criteria: * history of end stage renal disease or on dialysis; * prior kidney transplantation; * patients with a dnr order; * patients without written informed consent; * pregnancy; * moribund patients with expected death within 24 h or whose survival to 28 days was unlikely due to an uncontrollable comorbidity (i.e., end-stage liver or heart disease, untreatable malignancy)
exercise-induced collective rhabdomyolysis

Conditions: Rhabdomyolysis

Summary: rhabdomyolysis, which is a characteristic occurrence in associated with muscle cell necrosis, develops due to various causes.the investigators herein report a rare case of collective rhabdomyolysis after high intensity resistance training, including 35 teenagers（participants），in which markedly elevated levels of serum creatine kinase (ck) and serum myoglobin were observed. this high intensity resistance trainings is a part of military training(mt)，which all the middle school students must finish before admission。


Eligibility criteria:
inclusion criteria: * clinical diagnosis of rhabdomyolysis; * caused by military training; * informed consent； * must be able to cooperate with blood test. exclusion criteria: * caused by drugs and other reasons; * no hospitalization event

Keywords: rhabdomyolysis military training
molecular imaging of plaque vulnerability

Conditions: Plaque, Atherosclerotic

Summary: accumulating data in the literature suggests that radiolabeled-choline (18f-choline) is a sensitive molecular tracer for pet imaging that is taken up in activated cells and, as such, is able to identify active inflammatory sites. the investigators hypothesize that 18f-choline is also highly taken up in vulnerable plaques in comparison to the stable ones.

accumulation and subsequent activation of inflammatory cells in the atherosclerotic plaques play an essential role in transforming a stable plaque into a vulnerable plaque at risk to rupture. on this basis, the study aims to evaluate the diagnostic performance of 18f-choline pet in identifying ongoing inflammation within atherosclerotic plaques. the investigators hypothesize that 18f-choline pet is efficient in detecting intraplaque inflammation and identify vulnerable plaques that are prone to rupture in comparison to the stable ones. it is likely that by correlating the inflammatory status of an atherosclerotic plaque (on 18f-choline pet) with the presence of other vulnerable plaque features (on mr imaging) would be of high clinical relevance for clinical diagnosis of vulnerable plaques.

Eligibility criteria:
inclusion criteria: * patients known with symptomatic carotid artery stenosis (≥2 mm carotid plaque on duplex ultrasound), who are scheduled in the clinical setting to undergo a carotid endarterectomy or who are referred to conservative therapy; * age 18 years and older (no maximum age); * informed consent by signing informed consent form regarding this study. exclusion criteria: * dementia, pregnancy, nursing mothers; * serious neurological deficits at symptomatic side (hemi paralysis, complete aphasia); * severe heart failure nyha iii-iv and severe pulmonary dysfunction dependent on oxygen supply; * patients with contra-indications for mri (ferromagnetic implants like pacemakers or other electronic implants, metallic splinters in the eyes, vascular clips, claustrophobia, etc.).

Keywords: 18f-fluormethylcholine [f18] choline [f18] fluormethylcholine
a study of bms-986207 given alone and in combination with nivolumab or with nivolumab and ipilimumab in advanced solid tumors

Conditions: Broad Solid Tumor

Summary: the purpose of this study is to evaluate the safety and effectiveness of experimental medication bms-986207 by itself, in combination with nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.


Eligibility criteria:
inclusion criteria: * must have pre-existing or prior programmed death-ligand 1 (pd-l1) immunohistochemistry (ihc) results within 3 months of enrollment from testing of tumor tissue; pd-l1 expression must be tumor cell positive ≥ 1% for a participant to be eligible for enrollment * eastern cooperative oncology group (ecog) performance status of 0 or 1 * measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per response evaluation criteria in solid tumors (recist) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization exclusion criteria: * primary central nervous system (cns) disease, or tumors with cns metastases as the only site of disease. controlled brain metastases will be allowed to enroll * other active malignancy requiring concurrent intervention * uncontrolled or significant cardiovascular disease * active, known, or suspected autoimmune disease * nsclc without prior treatment in the advanced or metastatic setting (part 2c) other protocol-defined inclusion/exclusion criteria apply

Keywords: first line nsclc
volume restriction in esophageal carcinoma surgery: randomized clinical trial

Conditions: Esophageal Neoplasm

Summary: an exploratory single-centre randomized clinical trial was performed in order to investigate whether the fluid volume administered during esophageal carcinoma surgery affects pulmonary gas exchange and tissue perfusion.

a convenience sample of 16 patients admitted to the department of thoracic surgery university hospital centre zagreb and scheduled for esophageal carcinoma surgery were enrolled prospectively in the study between june 2011 and august 2012. patients were randomly allocated into two groups, one of which received ≤ 8ml/kg/h of intraoperative fluid ("restrictive group") and another that received \> 8 ml/kg/h of fluid ("liberal group"). patients were excluded if they were younger than 18 years; if they had severe lung disease, chronic renal insufficiency, or a physical status classification \> iii on the american society of anesthesiologists (asa) scale; or if it was impossible to perform epidural catheter placement or thoraco-phreno-laparotomy. all patients underwent esophagectomy carried out according to the lewis-tanner approach. data on arterial oxygen partial pressure (pao2), inspired oxygen fraction (fio2), and the ratio pao2/fio2 were collected 10 min after anesthesia was induced and again 6 h after surgery. data on the metabolic markers creatinine and lactate were collected 10 min after anesthesia induction and 6 h after surgery. anova tests were performed to determine significant differences in mean values between study groups. independent-sample t-tests were used to test differences in mean values between the restrictive and liberal groups for each of the two sets of measurements separately (10 minutes after anesthesia induction and 6 hr after surgery). p \< 0.05 was considered significant.

Eligibility criteria:
inclusion criteria: * esophageal carcinoma * lewis tanner procedure (median laparotomy and right thoracotomy) exclusion criteria: * younger than 18 years * severe lung disease * chronic renal insufficiency * a physical status classification \> iii on the american society of anesthesiologists (asa) scale * impossible to perform epidural catheter placement * thoraco-phreno-laparotomy

Keywords: intraoperative fluid management esophageal carcinoma surgery gas exchange tissue perfusion
use of indocyanine green in pancreas surgery

Conditions: Pancreatic Carcinoma

Summary: this study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.

primary objective: i. to determine if altered measurement results of icg after pancreatectomy is associated with leak rates. outline: this is an observational study. patients receive indocyanine green intravenously (iv) during surgery, undergo imaging and have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * participant scheduled for open pancreaticoduodenectomy or distal pancreatectomy for any diagnosis * participant ≥ 18 years of age * ability to understand nature and individual consequences of clinical trial * written informed consent from participant or legally authorized representative * for participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention * participant needs to have an operative drain (any closed suction drain) after the procedure * participants that do not require arterial reconstruction * participants that require minor portal venous recounstructions including patch venoplasty exclusion criteria: * patients with previous history of adverse reaction to contrast dye, icg or components of the dye * prior pancreatectomy * known diagnosis of hepatic insufficiency, hepatitis, liver fibrosis or cirrhosis, or chronic pancreatitis * because this study focuses on hypoperfusion, patients will be excluded if in postoperative day 3-5 had any of the following: persistent sbp \ 2 units intraoperatively or 1 postoperatively, vasopressor treatment or acls protocol initiation * organ failure, anuria or nsqip-identified complication will be reviewed by pi and attending surgeon and excluded * patients that require arterial reconstruction as part of their procedures
to evaluate the effect of wound infiltration with bupivacaine for post-operative pain relief after laparoscopic cholecystectomy

Conditions: Post-operative Pain

Summary: to evaluate the effect of wound infiltration with 0.25% bupivacaine in laparoscopic cholecystectomy in terms of pain severity, patient satisfaction level, quality of life, hospital stay and return to job and normal activities.


Eligibility criteria:
inclusion criteria * patients scheduled to undergo laparoscopic cholecystectomy under general anesthesia at department of surgery and department of hepatobiliary system, bsmmu * patients who are eligible according to asa ⅰ -ⅱ * female or male, age ≥18 years * patients who are scheduled for same anesthetic technique and surgical procedure for laparoscopic cholecystectomy * discharge of patient between 12 hour to 36 hour after performing procedure * patients given consent for enrollment in study exclusion criteria * patients known to be allergic to certain recommended drugs * if patients have history of psychiatric illness * patients on chronic analgesic therapy for any other indication * patients who are scheduled for different anesthetic technique and surgical procedure for laparoscopic cholecystectomy * duration of surgery more than 1 hour * patients undergoing laparoscopic cholecystectomy for complex gallbladder disease such as incidental gallbladder pancreatitis, gallstone pancreatitis, cholecystoduodenal fistula, mirizzi syndrome * special population group such as children, pregnant woman, patients with cirrhosis, diabetics * duration of operative procedure more than 1 hour
personalized remotely guided preventive exercise therapy for a healthy heart

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: in the priority study, we aim to provide the clinical evidence base for the use of a new hybrid exercise intervention, which includes remotely guided home-based exercise, as an accessible, clinical and cost-effective treatment to prevent the deleterious effects of sedentary aging on the heart and forestall the development and progression towards overt hfpef.


Eligibility criteria:
inclusion criteria: men and women (hf stage a) aged \> 30 yrs: * treated or untreated patients with hypertension (blood pressure 130/80 - 159/99 mmhg) and/or * patients with prediabetes (impaired fasting glucose and/or insulin resistance) with either: fasting plasma glucose: 100 to 125 mg/dl (5.6-6.9 mmol/l) hemoglobine a1c: 5.7% to 6.4% homeostatic model assessment of insulin resistance (homa-ir) index above 75% of population distribution (\>2.0) and/or * patients with obesity with 30 kg/m² ≥ body mass index ≤ 42 kg/m² * patients with subclinical signs of diastolic dysfunction without symptoms (hf stage b disease) * men and women with diagnosis of hf stage c: i.e. patients who have a total score ≥ 5 points according to the recent recommendation paper on how to diagnose heart failure with preserved ejection fraction from the heart failure association of esc. all participants should be on optimal medical treatment and stable with regard to symptoms and pharmacotherapy for at least 4 weeks before enrollment in the study. all participants should have internet access at home. exclusion criteria: * significant illness during the last 6 weeks * known severe ventricular arrhythmia with functional or prognostic significance * significant myocardial ischemia, hemodynamic deterioration or exercise-induced arrhythmia at baseline testing * co-morbidity that may significantly negatively influence one-year prognosis * functional or mental disability that may limit execution of prescribed exercise * severe chronic obstructive pulmonary disease (fev1 \< 50%) * nyha class iv * participation in another clinical interventional trial * cognitive limitation
effect of magnesium sulphate on coagulation

Conditions: Myoma

Summary: arterial and venous thrombotic events are the clinical manifestation of postoperative hypercoagulability. altered serum magnesium may play a role in the balance of coagulation. in this study, the investigators investigated the effect of magnesium sulphate on the postoperative coagulation change in total intravenous anesthesia (tiva).


Eligibility criteria:
inclusion criteria: * asa ⅰ-ⅱ patients undergoing pelviscopic gynecologic operation under general anesthesia. exclusion criteria: * pregnancy * previous known hematologic disorder * recent medication interfering with hemostasis * severe anemia * liver disease * cardiovascular or respiratory disease
adenosine as an adjunct to blood cardioplegia

Conditions: Pathological Processes; Cardiomyopathies

Summary: myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. the main principle of myocardial protection in cardiac surgery is to preserve myocardial function by preventing ischemia with blood cardioplegia . previous studies have shown that adenosine as an adjunct to blood cardioplegia can be safely used in cardiac surgery. in the amphia hospital, adenosine is already used as standard care as an initial cardioplegic bolus in minimally invasive port access operations. whether, adenosine as an adjunct to intermittent warm blood cardioplegia, has an added value remains unclear. therefore the investigators would like to investigate the effect of the addition of adenosine to standard intermittent warm blood cardioplegia in patients scheduled for minimally invasive, port access operations (mitral valve surgery). half of the participants will receive standard intermittent warm blood cardioplegia, while the other half will receive intermittent warm blood cardioplegia enriched with adenosine.

myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. the main principle of myocardial protection in cardiac surgery is to preserve myocardial function by preventing ischemia with blood cardioplegia . previous studies have shown that adenosine as an adjunct to blood cardioplegia can be safely used in cardiac surgery. in the amphia hospital, adenosine is already used as standard care as an initial cardioplegic bolus in minimally invasive port access operations. whether, adenosine as an adjunct to intermittent warm blood cardioplegia, has an added value remains unclear. therefore the investigators would like to investigate whether the addition of adenosine to standard intermittent warm blood cardioplegia reduces the 6-hours post-operative cardiac troponin t (ctnt) in patients scheduled for minimally invasive, port access operations (mitral valve surgery).

Eligibility criteria:
inclusion criteria: * elective cardiac surgical patients * minimally invasive, port access surgery (mitral valve surgery) exclusion criteria: * all non-minimally invasive, port access surgery * theophylline or dipyridamole use up to 24 hours prior to surgery * products that contain caffeine of theobromine up to 12 hours prior to surgery (coffee, chocolate, energizing drinks (e.g. red bull), tea, soda (coke), etc)

Keywords: cardioplegia cardiac surgery adenosine therapeutic uses intermittent warm blood cardioplegia minimally invasive surgery minimally invasive mitral valve plasty (mini-mpl) minimally invasive mitral valve replacement (mini-mvr)
a multi-risk factor strategy vs a guideline-based approach in achieving blood pressure and lipid goals in hypertensives at extra risk

Conditions: Dyslipidemia; Hypertension

Summary: the purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (caduet plus therapeutic lifestyle changes (tlc) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (ldl-c) goals compared with a joint national committee 7/ national cholesterol education program adult treatment panel iii (jnc 7/ncep atp iii) guideline-based approach (norvasc plus tlc regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.


Eligibility criteria:
inclusion criteria: * subjects with diagnosed hypertension receiving treatment with norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia. exclusion criteria: * subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then norvasc, \>3 antihypertensive agents (including norvasc) * subjects that have not been on a stable dose of norvasc for at least 4 weeks * subjects with a history of coronary heart disease, stroke, or pulmonary vascular disease (pvd)
femoral external rotation measured on ct and mri

Conditions: Knee Osteoarthritis

Summary: this study aims to compare the femoral external rotation measured on ct and mri to that measured intraoperatively to clarify the influence of residual cartilage on posterior condyle on the preoperative planning of total knee arthroplasty.


Eligibility criteria:
inclusion criteria: 1. 50-85 years old 2. patients with osteoarthritis (kellgren-lawrence grade iii or iv) underwent total knee arthroplasty. exclusion criteria: 1. patients cannot endure tka due to severe heart failure, arrhythmia, myocardial infarction, infection or other reason. 2. patients who cannot undergo mri.
a study of lp-168 in healthy volunteers

Conditions: Multiple Sclerosis; NMO Spectrum Disorder

Summary: this is a phase i study designed to assess the safety, tolerability and pharmacokinetics of lp-168 in healthy human volunteers.

this study will enroll 70 healthy subjects, will set 4 sad and 3 mad dose cohorts, with 10 subjects in each dose cohort. subjects will be assigned to l-168 or placebo group by ratio of 8:2 in each cohort. sentinel subjects will be used in each dose cohort during the single dose phase.

Eligibility criteria:
inclusion criteria: * subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer * subjects (including partners) are willing to take effective contraception measures during study and within 3 months after last dose * male and female healthy subjects aged 18 to 55 years old * male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg * subjects able to understand and comply with study requirements * willing to sign the informed consent exclusion criteria: * abnormal vital signs, physical examination or laboratory tests with clinical significance * abnormal ecg or echocardiography with clinical significance * hepatitis b virus, hepatitis c virus, hiv and syphilis test positive. covid-19 dna positive. * subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug * subjects who have consumed diets that may alter the activity of liver metabolic enzymes within 7 days before administration the study drug * subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug * subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion * female subjects are breastfeeding or pregnant * subjects who have a history of drug/ alcohol/ tobacco abuse * subjects who have had a blood donation or massive blood loss within three months before screening; or had surgery within six months before screening * subjects who have participated in other clinical trial within three months before screening * subjects have special dietary requirements or cannot tolerate a standard meal